Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Medical Device

Medtronic’s Harmony TPV System Gains CE Mark for Minimally Invasive Heart Valve Treatment

Fineline Cube Jan 9, 2025

US-Irish firm Medtronic (NYSE: MDT) has announced that its Harmony Transcatheter Pulmonary Valve (TPV) System...

Company Deals

Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology

Fineline Cube Jan 9, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia,...

Company Drug

Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China

Fineline Cube Jan 9, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...

Company Deals

Araris Biotech and Chugai Pharmaceutical Collaborate on Novel ADC Development

Fineline Cube Jan 9, 2025

Switzerland-based oncology biotech Araris Biotech AG has announced a research collaboration and option to license...

Company Deals Drug

Mirror Biologics and Merck KGaA Collaborate on Phase II Trial for Colorectal Cancer Immunotherapy

Fineline Cube Jan 9, 2025

US-based Mirror Biologics, Inc., an off-the-shelf immunotherapy developer, has announced a clinical trial collaboration and...

Company Drug

Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease

Fineline Cube Jan 9, 2025

US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast...

Company Deals

Boston Scientific Set to Acquire Bolt Medical for Up to USD 900 Million

Fineline Cube Jan 9, 2025

US major Boston Scientific Corporation (NYSE: BSX) is set to acquire Bolt Medical, Inc., a...

Company Policy / Regulatory

China’s Central Committee and State Council Outline Reforms for Elderly Care Services

Fineline Cube Jan 9, 2025

The Communist Party of China (CPC) Central Committee and State Council have released the Opinions...

Company Deals

Xtalpi’s Ailux Biologics Partners with UCB for AI-Driven Drug Discovery

Fineline Cube Jan 9, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., has announced that its subsidiary...

Policy / Regulatory

Shanghai Opens Door to Wholly Foreign-Owned Hospitals in Key Areas

Fineline Cube Jan 9, 2025

The Shanghai Municipal Health Commission, along with three other bureaus, has jointly released the “Work...

Policy / Regulatory

NHSA Strengthens Medical Security Rights for Workers in China

Fineline Cube Jan 9, 2025

China’s National Healthcare Security Administration (NHSA) has released the “Notice on Further Strengthening the Protection...

Company Deals

Duality Biologics and Avenzo Ink Exclusive License for DB-1418/AVZO-1418

Fineline Cube Jan 8, 2025

On January 8, Duality Biologics, Inc. (Duality Bio) and Avenzo Therapeutics, Inc. (Avenzo) jointly announced...

Company Drug

MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26

Fineline Cube Jan 8, 2025

US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received...

Company Drug

Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication

Fineline Cube Jan 8, 2025

Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...

Company Medical Device

GE Healthcare’s Allia IGS Pulse Receives NMPA Clearance for Launch in China

Fineline Cube Jan 8, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has announced...

Company Deals Drug

Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418

Fineline Cube Jan 8, 2025

US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...

Company Deals

Inceptor Bio and GRIT Biotechnology Partner to Advance CAR-T Therapy IB-T101 for Solid Tumors

Fineline Cube Jan 8, 2025

US-based Inceptor Bio has entered into a partnership with Chinese firm GRIT Biotechnology to advance...

Company Deals

Kexing and Kelun Partner to Expand Overseas Business for Generic Drugs and Therapies

Fineline Cube Jan 8, 2025

China-based firms Kexing Pharmaceutical (SHA: 688136) and Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) have...

Company Deals

PKU 1st Hospital Partners with Baheal Pharmaceutical on Integrin-Targeted Inhibitor Project

Fineline Cube Jan 8, 2025

Peking University First Hospital (PKU 1st Hospital) has partnered with China-based health services and distribution...

Company Deals

Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project

Fineline Cube Jan 8, 2025

Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...

Posts pagination

1 … 226 227 228 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.